news.google.com· FierceBiotech·· 12 hours agoScore26
ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up - Fierce Biotech
In brief
At ESMO, GSK's head of oncology R&D said the mo-rez data reinforce confidence in the ADC as phase 3 development accelerates.
Source: news.google.com · news.google.com